Approval · Notice of Compliance 25129 · 2021
VFEND: Notice of Compliance 25129
Issued February 3, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 25129
- Date
- February 3, 2021
- Company
- Pfizer Canada UlcKirkland, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- To update the Product Monograph with drug-drug interactions with ivabradine and venetoclax.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| VFEND | Not yet assigned | — |
Medicinal ingredients
- VORICONAZOLE 50 MG per TAB
- VORICONAZOLE 200 MG per TAB
- VORICONAZOLE 200 MG per VIAL
- VORICONAZOLE 3 G per BOTTL